Newron in Talks to License Experimental Schizophrenia Drug
- Possible deal may come in second half, CEO says in interview
- Potential buyers await key data to be released in March
This article is for subscribers only.
Newron Pharmaceuticals SpA has held initial discussions with potential partners about licensing an experimental drug to treat schizophrenia, a mental health condition with no cure.
“We see a good chance of a licensing deal in the second half of the year,” Chief Executive Officer Stefan Weber said in a telephone interview late on Tuesday.